Vectura in global development programme

Vectura has signed a development and licence agreement with Mundipharma International and a US independent associated company as the global development and commercialisation partner for the VR2076 (previously SKP-2076) pressurised Metered Dose Inhaler (pMDI) ICS/LABA/LAMA triple programme.

In December 2015, the companies entered into a feasibility and option agreement and following successful completion of the feasibility work, which Vectura was responsible for, Mundipharma and the US associated independent company have now confirmed they will exercise the option to develop and commercialise VR2076 initially in asthma.

The exercise of this option triggers a payment to Vectura of €1.5 million. The Group’s R&D investment guidance for 2016 and 2017, provided recently in its interim results statement in November, remains unchanged.

Further total potential milestone payments up to €46.5 million are receivable linked to development, regulatory and launch progress of the programme as well as royalties on any future net sales of the product.

The royalty rate on this novel product development programme, where Vectura has been responsible for the formulation development, is initially around a mid-single digit percentage but could increase depending on sales.

This agreement also includes the potential for further development of the triple combination treatment for chronic obstructive pulmonary disease (“COPD”).

If Mundipharma decides to develop the programme in COPD, Vectura is eligible for further potential milestones linked to the regulatory progress of the programme up to €20.0 million as well as royalties on any future net sales of the product. The royalty rate on net sales for the COPD indication product would be the same as the asthma indication product. In addition, Vectura will also receive one-off undisclosed sales milestones should net sales of both the asthma and COPD products achieve certain predetermined levels.

The first regulatory filings of VR2076 are planned in the EU for late 2022/early 2023.

Story provided by StockMarketWire.com

Merryn

Claim 12 issues of MoneyWeek (plus much more) for just £12!

Let MoneyWeek show you how to profit, whatever the outcome of the upcoming general election.

Start your no-obligation trial today and get up to speed on:

  • The latest shifts in the economy…
  • The ongoing Brexit negotiations…
  • The new tax rules…
  • Trump’s protectionist policies…

Plus lots more.

We’ll show you what it all means for your money.

Plus, the moment you begin your trial, we’ll rush you over THREE free investment reports:

‘How to escape the most hated tax in Britain’: Inheritance tax hits many unsuspecting families. Our report tells how to pass on up to £2m of your money to your family without the taxman getting a look in.

‘How to profit from a Trump presidency’: The election of Donald Trump was a watershed moment for the US economy. This report details the sectors our analysts think will boom from Trump’s premiership, and gives specific investments you can buy to profit.

‘Best shares to watch in 2017’: Includes the transcript from our roundtable panel of investment professionals – and 12 tips they’re currently tipping. The report also analyses key assets, including property, oil and the countries whose stock markets currently offer the most value.